{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:21:10Z","timestamp":1787016070199,"version":"build-2736575974"},"reference-count":23,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T00:00:00Z","timestamp":1582156800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Institutional training grant from the National Heart, Lung, and Blood Institute","award":["T32 HL007093"],"award-info":[{"award-number":["T32 HL007093"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>D\u2010negative patients are at risk of developing an alloantibody to D (anti\u2010D) if exposed to D during transfusion. The presence of anti\u2010D can lead to haemolytic transfusion reactions and haemolytic disease of the newborn. Anti\u2010D alloimmunization can also complicate allogeneic haematopoietic stem cell transplantation (HSCT) with haemolysis and increased transfusion requirements. The goal of this study was to determine whether cancer centres have transfusion practices intended to prevent anti\u2010D alloimmunization with special attention in patients considered for HSCT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and materials<\/jats:title>\n                    <jats:p>\n                      To understand transfusion practices regarding D\u2010positive platelets in D\u2010negative patients with large transfusion needs, we surveyed the 28 cancer centres that are members of the National Comprehensive Cancer Network\n                      <jats:sup>\u00ae<\/jats:sup>\n                      (NCCN\n                      <jats:sup>\u00ae<\/jats:sup>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nineteen centres responded (68%). Most centres (79%) avoid transfusing D\u2010positive platelets to RhD\u2010negative patients when possible. Four centres (21%) avoid D\u2010positive platelets only in D\u2010negative women of childbearing age. If a D\u2010negative patient receives a D\u2010positive platelet transfusion, 53% of centres would consider treating with Rh immune globulin (RhIg) to prevent alloimmunization in women of childbearing age. Only one centre also gives RhIg to all D\u2010negative patients who are HSCT candidates including adult men and women of no childbearing age.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>There is wide variation in platelet transfusion practices for supporting D\u2010negative patients. The majority of centres do not have D\u2010positive platelet transfusion policies focused on preventing anti\u2010D alloimmunization specifically in patients undergoing HSCT. Multicentre, longitudinal studies are needed to understand the clinical implications of anti\u2010D alloimmunization in HSCT patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/vox.12899","type":"journal-article","created":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T22:21:29Z","timestamp":1582237289000},"page":"334-338","source":"Crossref","is-referenced-by-count":5,"title":["Mitigation strategies for anti\u2010D alloimmunization by platelet transfusion in haematopoietic stem cell transplant patients: a survey of NCCN\n                    <sup>\u00ae<\/sup>\n                    centres"],"prefix":"10.1111","volume":"115","author":[{"given":"Jacqueline N.","family":"Poston","sequence":"first","affiliation":[{"name":"Department of Medicine Division of Hematology University of Washington Seattle WA USA"},{"name":"Seattle Cancer Care Alliance Seattle WA USA"},{"name":"Fred Hutchinson Cancer Research Center Seattle WA USA"},{"name":"BloodworksNW Research Institute Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Sugalski","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network Plymouth Meeting PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry B.","family":"Gernsheimer","sequence":"additional","affiliation":[{"name":"Department of Medicine Division of Hematology University of Washington Seattle WA USA"},{"name":"Seattle Cancer Care Alliance Seattle WA USA"},{"name":"Fred Hutchinson Cancer Research Center Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Marc Stewart","sequence":"additional","affiliation":[{"name":"Seattle Cancer Care Alliance Seattle WA USA"},{"name":"Fred Hutchinson Cancer Research Center Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5183-6471","authenticated-orcid":false,"given":"Monica B.","family":"Pagano","sequence":"additional","affiliation":[{"name":"Department of Medicine Division of Hematology University of Washington Seattle WA USA"},{"name":"Department of Laboratory Medicine Transfusion Medicine Division University of Washington Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,2,20]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.5696.593"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.4.5624.139"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2016.05.008"},{"key":"e_1_2_9_5_1","first-page":"301","article-title":"Matching for the D antigen in haematopoietic progenitor cell transplantation: definition and clinical outcomes","volume":"12","author":"Cid J","year":"2014","journal-title":"Blood Transfus"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2010.01435.x"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000185"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1990.tb00856.x"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1053\/tmrv.2003.50003"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.02953.x"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13158"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1159\/000490122"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1994.34294143938.x"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1994.tb00318.x"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14937"},{"key":"e_1_2_9_16_1","volume-title":"Technical Manual","author":"American Association of Blood Banks","year":"2017"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13077"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.1971.tb04425.x"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21705"},{"key":"e_1_2_9_20_1","first-page":"632","article-title":"Anti\u2010D antibody of exclusive IgM class after minor Rh(D)\u2010mismatched BMT","volume":"16","author":"Esteve J","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"e_1_2_9_21_1","first-page":"215","article-title":"Engraftment of RH\u2010positive marrow in a recipient with RH antibody","volume":"9","author":"Berkman EM","year":"1977","journal-title":"Transplant Proc"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1159\/000206308"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30196-5"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03151.x"}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fvox.12899","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.12899","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/vox.12899","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.12899","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T03:38:09Z","timestamp":1693971489000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vox.12899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,20]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.1111\/vox.12899"],"URL":"https:\/\/doi.org\/10.1111\/vox.12899","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"value":"0042-9007","type":"print"},{"value":"1423-0410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,20]]}}}